Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nisotirostide alone and with dulaglutide in type 2 diabetes
NCT05377333Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nisotirostide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 16 weeks. Started Jun 2022; status: completed.
02
Drugs
nisotirostide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05377333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377333.